Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.

Cliff ERS, Pelaez GD, Wan F, Iyengar V, Zhou J, Chung K, Abdel-Razeq N, Allen J, Major A, Sharp J, Epperla N, Gould P, Cherng HJ, Houshyar S, Wallace DS, Lynch RC, Kallam A, Mei MG, Merryman RW, Fleyshman M, Rhodes JM, Kidwell A, Fenske TS, Malakhov N, Mulvey E, Watkins MP, Alhaj Moustafa M, Hilal T, Nowakowski GS, Wang Y, Torka P, Russler-Germain DA.

Open source

DOI: 10.1158/1078-0432.ccr-25-2392
Published: 2026-01-01
Container: Clin Cancer Res
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1158/1078-0432.ccr-25-2392,
  title = {Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.},
  author = {Cliff ERS and  Pelaez GD and  Wan F and  Iyengar V and  Zhou J and  Chung K and  Abdel-Razeq N and  Allen J and  Major A and  Sharp J and  Epperla N and  Gould P and  Cherng HJ and  Houshyar S and  Wallace DS and  Lynch RC and  Kallam A and  Mei MG and  Merryman RW and  Fleyshman M and  Rhodes JM and  Kidwell A and  Fenske TS and  Malakhov N and  Mulvey E and  Watkins MP and  Alhaj Moustafa M and  Hilal T and  Nowakowski GS and  Wang Y and  Torka P and  Russler-Germain DA.},
  year = {2026},
  journal = {Clin Cancer Res},
  doi = {10.1158/1078-0432.ccr-25-2392},
  url = {https://doi.org/10.1158/1078-0432.ccr-25-2392}
}

RIS

TY  - JOUR
TI  - Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.
AU  - Cliff ERS
AU  -  Pelaez GD
AU  -  Wan F
AU  -  Iyengar V
AU  -  Zhou J
AU  -  Chung K
AU  -  Abdel-Razeq N
AU  -  Allen J
AU  -  Major A
AU  -  Sharp J
AU  -  Epperla N
AU  -  Gould P
AU  -  Cherng HJ
AU  -  Houshyar S
AU  -  Wallace DS
AU  -  Lynch RC
AU  -  Kallam A
AU  -  Mei MG
AU  -  Merryman RW
AU  -  Fleyshman M
AU  -  Rhodes JM
AU  -  Kidwell A
AU  -  Fenske TS
AU  -  Malakhov N
AU  -  Mulvey E
AU  -  Watkins MP
AU  -  Alhaj Moustafa M
AU  -  Hilal T
AU  -  Nowakowski GS
AU  -  Wang Y
AU  -  Torka P
AU  -  Russler-Germain DA.
PY  - 2026
JO  - Clin Cancer Res
DO  - 10.1158/1078-0432.ccr-25-2392
UR  - https://doi.org/10.1158/1078-0432.ccr-25-2392
ER  -

APA

ERS, C., GD, P., F, W., V, I., J, Z., K, C., N, A., J, A., A, M., J, S., N, E., P, G., HJ, C., S, H., DS, W., RC, L., A, K., MG, M., RW, M., M, F., JM, R., A, K., TS, F., N, M., E, M., MP, W., M, A. M., T, H., GS, N., Y, W., P, T., & DA., R. (2026). Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell Lymphoma.. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-25-2392

Source records

europe-pmc · retrieved 2026-09-27T16:00:49.269Z